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Objective: The main aim of this survey was to determine the frequency of self-reported lower
limb or foot and ankle complications experienced by participants with systemic lupus erythe-
matosus (SLE). A secondary aim was to determine the frequency of treatments that have been
received or that participants with SLE may like to receive if offered. Method: A quantitative,
cross-sectional, self-reported survey design was utilized. The developed survey was checked for
face and content validity prior to patient partner cognitive debriefing in order to ensure
usability, understanding of the process of completion and of the questions posed. The full
protocol for survey development has been published previously. Results: This is the first
comprehensive national UK survey of lower limb and foot health problems reported by
participants with SLE. A high prevalence of vascular, dermatological and musculoskeletal
complications was reported by survey respondents. Additionally, whilst the relative prevalence
of sensory loss was low, a quarter of people reported having had a fall related to changes in
foot sensation demonstrating a previously unknown rate and cause of falls. Conclusion:
Complications related to vascular, dermatological and musculoskeletal health are identified
as particularly prevalent in participants with SLE. Further, there is a suggestion that the
provision of interventions to maintain lower limb health is highly varied and lacks national
standardization, despite there being a strong indication of participant reported need.
The findings of this work can be used to inform care guideline development in addition to
identifying areas for future research. Lupus (2016) 0, 1–7.
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Background
Systemic lupus erythematosus (SLE) is a complex,
chronic, multi-system autoimmune disease which
varies in prevalence and incidence depending
upon ethnicity and is diagnosed about nine times
more frequently in women than men.1,2 In the UK
approximately 25,000 people have a diagnosis of
SLE.3 The disease is highly heterogeneous in that
it varies in clinical and serological manifestations
and severity between individuals. Disﬁgurement
caused by the involvement of skin and joints3 can
aﬀect the patient’s perception of body image and
sexuality and can have an impact on emotional
health4 and overall quality of life.5
Involvement of the musculoskeletal system
is common during the clinical course of
SLE, occurring in up to 95% of patients, with
joint pain being the ﬁrst presenting symptom in
up to 50% of cases.6 The extra-articular manifest-
ations of SLE include soft tissue pathology such as
capsular swelling, synovial hypertrophy (thickening
of joint lining) and tenosynovitis,7 which can lead
to tendon rupture8 or tendon contracture.9
Tendons are the force transmitting units of
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the musculoskeletal system, but due to their
low metabolic rate and slow healing, injury can
result in considerable morbidity and prolonged
disability.10,11 In relation to the symptoms asso-
ciated with muscle involvement, these can range
in severity from mild aches in up to 80% of cases
to painful inﬂammatory myositis in up to 11% of
cases.7
In addition to the musculoskeletal involvement
in cases of SLE, people may also present with
vasculopathy. Vascular involvement can be either
a direct complication of SLE or develop as
comorbidity and represents one of the most
frequent causes of death.12 Mathieu et al.13 identi-
ﬁed that abnormal vascular reactivity and coagulo-
pathy both contribute to an increased risk
of atheroma and therefore recommend careful
monitoring for any vascular change with the aim
of preventing tissue necrosis and ultimately ampu-
tation or death.
Focussing on the foot, a narrative review of
the literature14 identiﬁed that SLE aﬀects foot
and lower limb morbidity and that these have
the potential to impact upon health related quality
of life. However, the scale of these problems is
unclear and little research in this area has been
completed to date.15 It could be speculated that
the altered musculoskeletal, peripheral neurovascu-
lar and tissue health experienced by people with
SLE renders their feet particularly susceptible
to deformity, poor function, ulceration and/or
infection and pain. However the eﬀects and extent
of SLE upon body systems within the periphery
are unclear; e.g. with consideration to neurological
function, the extent of patient reported motor
neuropathy (e.g. muscle weakness), sensory
neuropathy (e.g. lost pressure detection) or auto-
nomic neuropathy (e.g. poor temperature regula-
tion) is unclear. Further, the attention given to
patients’ feet during the clinical consultation may
be limited, as has been evidenced for people with
rheumatoid arthritis.16 Thus, the opportunity to
provide timely advice and clinical intervention is
missed. As such, there is a need to determine the
prevalence of lower limb or foot and ankle compli-
cations experienced by people with SLE. Thus, the
main aim of this survey was to determine the fre-
quency of self-reported lower limb or foot
and ankle complications experienced by people
with SLE. A secondary aim was to determine
the frequency of treatments that have been received
or that people with SLE may like to receive if
oﬀered.
Methods
Ethics, consent and permissions
Ethical approval for the study was granted by
the University of Salford (HSCR14/25) and
NRES (14/SC/1009). All research was completed
in accordance with the Declaration of Helsinki
guidelines for research practice. Information
about the purpose and intended use of the study
was included in a covering letter as part of the
survey data sheet. Consent to take part in the
survey was considered implicit following the com-
pletion and return of the form.
Study and survey design
A quantitative, cross-sectional, self-reported survey
design was utilized. To aid survey design a patient
and practitioner advisory group was formed. The
group was comprised of members of the research
team, rheumatologists, podiatrists and participants
with SLE. An initial group meeting, held following
review of existing literature related to problems
associated with SLE, generated an item pool from
which the survey could be developed. From this
preliminary work, the survey was developed based
on the agreed themes, categories, question format
and overall structure.17 The survey was checked for
face and content validity prior to cognitive debrief-
ing in order to ensure usability, understanding of
the process of completion and of the questions
posed. The choice of language within the survey
was considered and advice sought during the
survey development process from the patient part-
ners. Where it was felt that the use of technical
terminology was appropriate, clarifying text was
also included; e.g. ‘Have you had any breaks in
the skin that have been slow to heal (known as
ulceration)?’. The full protocol for survey develop-
ment has been published previously.17
The ﬁnal survey consisted of ﬁve sections: 1.
Lower limb circulatory health; 2. Lower limb
nerve function; 3. Foot and ankle skin health;
4. Lower limb musculoskeletal health; and
5. Received or ‘needed’ foot and ankle treatments.
Survey distribution
The survey was distributed consecutively to all
eligible participants with SLE attending six UK
NHS Rheumatology departments, with whom
the research team are associated (Blackburn,
Christchurch, Leeds, Manchester, Salford and
Southampton), and distributed to all members
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of the Lupus UK membership register. Using this
approach, it was not possible to determine how
many people declined to participate in the survey.
Analysis
All analysis was completed using SPSS version 18.0
(Chicago, USA). Prior to analysis, data were
checked for inconsistencies, outliers or missing
information. Descriptive statistics (count and per-
centage data) were used throughout.
Results
Survey data
A total of 182 completed surveys were returned to
the research team. The reported age range of par-
ticipants was normally distributed, with the major-
ity of participants being within the ranges of 40–49
years and 50–59 years. The mean reported disease
duration was 14.6 (9.9) years. Nineteen partici-
pants were active smokers. The reported ethnicity
of participants was as follows: white n¼ 125,
black Caribbean n¼ 3, black African n¼ 3, black
other n¼ 3, Indian n¼ 7, Pakistani n¼ 7,
Bangladeshi n¼ 1, Chinese n¼ 6, other n¼ 4,
non-disclosed n¼ 23.
Lower limb circulatory health
Overall, 85% (n¼ 156) reported having experienced
some form of lower limb circulatory impairment.
As shown in Table 1, the most frequently reported
symptom of impaired circulation was night cramps
(74%; n¼ 135) and the least frequent was chilblains
(21%; n¼ 38).
The receipt of treatment for lower limb circula-
tory complications was reported by 18% (n¼ 32).
Reported treatments included prescribed medica-
tion use 66% (n¼ 21), surgical intervention 19%
(n¼ 6), or compression hosiery 6% (n¼ 2). The
nature of treatment was unspeciﬁed by three
people. The reported prescribed medications
included Nifedipine, Clopidogrel, Sildenaﬁl,
Cyclophosphamide, Iloprost or Epoprostenol
Sodium.
Lower limb nerve function
Overall, 16% (n¼ 29) reported having experienced
symptoms consistent with sensory neuropathy
(described as a ‘loss of feeling’ for the purposes of
this survey), whilst 25% (n¼ 46) reported having
had a fall because of altered sensation in their
feet. Whilst speciﬁc questions relating to painful
neuropathy were not included in the survey, 10
patients reported experiencing symptoms consistent
with neuropathic pain within the free text com-
ments section of the survey.
The receipt of treatment for lower limb nerve
complications was reported by 8% (n¼ 14).
Reported treatments included Amitriptyline or
Pregabalin, steroid injection, Extra-Corporeal
Shockwave Therapy, Low Level Laser Therapy or
Acupuncture.
Foot and ankle skin health
Overall, 86% (n¼ 157) reported having experienced
some form of foot or ankle skin health complaint.
As shown in Table 1, the most frequently reported
complication was callus or corn formation (71%;
n¼ 129) and the least frequent was ulceration
(24%; n¼ 44).
‘Having ever’ experienced viral skin infection
(verrucae pedis) was reported by 42% (n¼ 77),
fungal skin infection by 42% (n¼ 76) and fungal
nail infection (onychomycosis) by 36% (n¼ 66).
Comparatively, reported previous or current bac-
terial infection, for which antibiotic treatment was
Table 1: Reported prevalence of self-reported lower limb
complications experienced by people with systemic lupus
erythematosus
Ever n (%) Currently n (%)
Circulation
Raynaud’s 93 (51) 34 (19)
Chilblains 38 (21) 14 (8)
Intermittent claudication 99 (54) 30 (16)
Night cramps 135 (74) 33 (18)
Neurological
Sensory loss 29 (16) 12 (7)
Sensory loss related fall 46 (25) —
Skin health
Ulceration 44 (24) 15 (8)
Callus or corns 129 (71) 75 (41)
Onychocryptosis 68 (37) 23 (13)
Rashes or blistering 62 (34) 11 (6)
Skin infection
Tinea pedis 76 (42) 20 (11)
Onychomycosis 65 (36) 35 (19)
Verrucae pedis 76 (42) 16 (9)
Musculoskeletal health
Joint pain 145 (80) 60 (33)
Joint stiffness 134 (74) 50 (27)
Joint swelling 93 (51) 29 (16)
Change in foot shape 65 (36) —
Functional impairment 67 (37) 22 (12)
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issued, was lowest at 15% (n¼ 27) and 2% (n¼ 3)
respectively.
Lower limb musculoskeletal health
Overall, 158 (87%) reported having experienced
some form of lower limb musculoskeletal compli-
cation. As shown in Table 1, the most frequently
reported complication was joint pain (80%;
n¼ 145) and the least frequent was a change in
foot shape (36%; n¼ 65). A previous or current
episode of loss of function, such that it was diﬃcult
or impossible to walk, was reported by 37%
(n¼ 67) and 12% (n¼ 22) respectively.
Received or wanted foot and ankle treatments
Overall, 33% (n¼ 60) reported having ever dis-
cussed their foot health with a doctor (rheumatolo-
gist or general practitioner) and 23% (n¼ 41)
reported having ever been diagnosed with a speciﬁc
foot or ankle problem.
A summary of the frequency of the common
treatments reportedly received is shown in
Table 2. The number of participants who reported
that they thought they would beneﬁt from these
treatments is also shown. A further 27% (n¼ 50)
of participants additionally reported that they
thought they would beneﬁt from general foot
health and care advice.
Discussion
To our knowledge, this is the ﬁrst comprehensive
national UK survey of lower limb and foot health
problems reported by people with SLE. This novel
survey has captured the reported high prevalence of
vascular, dermatological and musculoskeletal
complications experienced by this group of partici-
pants. Additionally, whilst the relative prevalence
of sensory loss was low, a quarter of participants
reported having had a fall related to changes in foot
sensation. This demonstrates a previously unknown
potential cause of falls amongst people with SLE.
Awareness of potential falls risk factors creates
opportunity to target prevention strategies.
Importantly, this patient population is already at
increased fracture risk due to comorbid health
needs and/or treatments and therefore there is a
potentially large detrimental consequence of
falling.
Interestingly, the ﬁndings of this UK survey are
similar to those reported by Otter et al.18 in a cross-
sectional study completed in New Zealand. The
comparative reported prevalence of vascular,
musculoskeletal and neurological complications
are similar between studies suggesting that, despite
diﬀerences in methodological approach, the ﬁnd-
ings may on average accurately reﬂect the foot
health status of this group of participants.
However to date, to our knowledge, there is cur-
rently no comparative research available against
which it is possible to compare the prevalence of
infection (approximately half of participants) or
callus/corns (approximately three-quarters of par-
ticipants) identiﬁed in this survey.
There was a high prevalence of vascular compli-
cations and symptoms, with varied drug or surgical
intervention, reported. Of note, 85% of partici-
pants reported having experienced some form of
vascular complication whilst only 18% of partici-
pants reported having received treatment for
peripheral vascular health. The results of this
survey therefore suggest a current mismatch
between participant reported vascular symptoms
and treatment. Additionally, a range in treatment
approaches were reported. Overall, the authors sug-
gest that the ﬁndings of this survey show a potential
area for improved clinician and patient awareness
and standardization of clinical practice (e.g. iden-
tifying when prophylactic pharmacology, such as
Sildenaﬁl, is indicated). It is hypothesized by the
research team that this could be achieved nationally
through guidance documentation or locally
through advice and screening at each consultation
in order to detect and treat early changes and
reduce the risk of serious progressive consequences
such as ulceration and necrosis.19 Although not
evidenced by the ﬁndings of this study, arguably,
there is potential for non-drug treatment
approaches to also improve lower limb vascular
health (e.g. exercise for the reduction of intermit-
tent claudication symptoms), although further
Table 2: Treatment received and ‘‘would like to receive’’ to
aid foot health people with systemic lupus erythematosus
Treatment
Received
(NHS)
n (%)
Received
(Private)
n (%)
Would like
to receive
n (%)
Orthoses 49 (27) 10 (5) 51 (28)
Specialist footwear 12 (7) 4 (2) 19 (10)
Footwear advice 35 (19) 8 (4) 49 (27)
Removal of callus
or corns
20 (11) 21 (12) 49 (27)
Nail care 18 (10) 13 (7) 54 (30)
Nail surgery 12 (7) 3 (2) 9 (5)
Surgery 28 (15) 0 22 (12)
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research is required to determine the mobility
impact of SLE and to evaluate the potential eﬃcacy
of exercise/mobility prescription in participants
with SLE.20
Participants did note experiencing loss of feeling,
with symptoms of ‘numbness’ and/or neuropathic
pain also referenced in the free text comments
received. Additionally, a number of participants
reported falls as a consequence of altered sensation
in their feet. However, there is insuﬃcient detail in
the context of this survey to further clarify the exact
nature of the altered sensation experienced and
how this led to a fall; or indeed whether the fall
related speciﬁcally to factors directly related to
SLE. Further qualitative research that clariﬁes the
nature and impact of such problems experienced by
this group is warranted. It is also proposed that
mobility and falls may represent an important
and potentially under-appreciated area of concern
that requires further investigation.
Over a third of participants reported having ever
experienced an episode of musculoskeletal compli-
cation that resulted in an inability to walk. This has
a high potential for reduced mobility and subse-
quently may have far reaching impact on comorbid
health complications (e.g. further compromise of
vascular status or compound tissue deconditioning)
which does not appear to be addressed by current
health care practice for this population. There is a
need to further explore the impact of compromised
mobility experienced by this patient group on
health, work, socialization or quality of life.
Foot problems that are prevalent in the general
population such as corns, callus and nail thickening
were also evident in this group. However, it is the-
oretically possible that the consequences of these
problems can be progressive and multifactorial,
leading quickly to tissue breakdown, ulceration
with potential for resistant bacterial infection or
necrosis and delayed wound healing. In addition,
fungal and viral infections may become more wide-
spread due to the autoimmune nature of SLE and
the immunosuppressive medication that can be
used for its management. It is recommended that
further research is required to fully appreciate the
nature of infection prevalence, identiﬁcation and
risk management/treatment in this patient group.
The impact and burden of self-treatment for
repeated fungal infections is reported in free text
responses and a need for professional diagnosis
and advice about the most eﬀective treatments
suggested.
Despite the seemingly high prevalence of lower
limb complications reported, only a third of
respondents reported ever having been asked
about their foot health by a doctor and even
fewer reported having been given any speciﬁc diag-
nosis. However, it is possible that the patients do
not report these problems to a doctor, as talking
about feet may not be seen as a medical role; this
lack of disclosure is reported by Blake et al.21 in
their study of patients with rheumatoid arthritis. It
is currently unclear whether this is also the case for
people with SLE.
The most frequent intervention for foot prob-
lems reported in this survey was the provision of
foot orthoses. However, despite being the most fre-
quent intervention, this was only reported by 27%
of participants and a clear request for further assist-
ance was evidenced, especially for general foot
health education or nail and skin care. However,
further research is needed to evaluate the eﬀective-
ness of the range of potential foot health interven-
tions for this patient group. It is perhaps of note
that the number of participants reporting that they
would like to receive treatment is greater than those
who have had treatment of any kind. This repre-
sents a potentially unmet foot health care burden
and further research to better understand the spe-
ciﬁc nature of any unmet need is required.
There may be unknown responder bias evi-
denced within the ﬁndings of this survey and this
represents a limitation of this work; it may be that
those participants who have previously experienced
complications are more likely to complete and
return the survey. The results of the survey may
also be subject to recall bias; e.g. participants may
over or under-report phenomena depending upon
their ability to accurately recall their past experi-
ences. Further the survey was limited to a UK
population although data were collected from
varied geographical locations nationally. Globally,
SLE is demographically variable and there is the
need to replicate this survey in other global con-
texts to fully appreciate the ranging prevalence
and burden of poor foot health for people with
SLE. Due to the self-reported nature of the
survey, it was not possible to ascertain the partici-
pants’ current SLE disease activity. The ﬁndings of
this initial survey could therefore be enhanced with
the completion of disease activity and damage indi-
ces through additional clinical study.
Despite the limitations, this is the ﬁrst UK
survey to obtain data about the prevalence and
management of self-reported foot problems experi-
enced by participants with SLE. The ﬁndings indi-
cate that foot health should be part of a health care
consultation. A particular focus on vascular, der-
matological and musculoskeletal complications is
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indicated although neurological health and falls
risk should also be considered.
Conclusion
This novel national survey demonstrates a high
prevalence of previously unreported lower limb
and foot health complications experienced by
participants with SLE and therefore achieves the
primary research aim. Complications related to
vascular, dermatological and musculoskeletal
health are identiﬁed as particularly prevalent in
participants with SLE. The frequency of treatments
reported was relatively low compared to the
reported prevalence of complication or reported
perceived need. The type of treatments currently
oﬀered are variable and appear to lack national
standardization. Overall, there is a high prevalence
of lower limb complications reported by partici-
pants with SLE for which treatment is currently
reported as nationally variable or not oﬀered,
although is perceived as needed by the majority.
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